Clinical trials
Aneurysm trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Unknown status | 6 |
| Active, not recruiting | 5 |
| Recruiting | 4 |
| Terminated | 3 |
| Suspended | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Radboud University Medical Center | 4 |
| Vascutek Ltd. | 4 |
| JOTEC GmbH | 2 |
| Rijnstate Hospital | 2 |
| W.L.Gore & Associates | 2 |
| Amsterdam UMC, location VUmc | 1 |
| Canisius-Wilhelmina Hospital | 1 |
| Cook Research Incorporated | 1 |
| Endologix | 1 |
| Evasc Medical Systems Corp. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aneurysm | 27 |
| Aortic Aneurysm, Abdominal | 7 |
| Aortic Aneurysm, Thoracic | 5 |
| Aortic Dissection | 4 |
| Penetrating Atherosclerotic Ulcer | 3 |
| Aortic Aneurysm | 2 |
| Aortic Diseases | 2 |
| Hypertension | 2 |
| Inflammation | 2 |
| Aneurysm, Aortic Arch | 1 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.